GB8817743D0
(en)
|
1988-07-26 |
1988-09-01 |
Fujisawa Pharmaceutical Co |
Fr901228 substance & preparation thereof
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5545522A
(en)
|
1989-09-22 |
1996-08-13 |
Van Gelder; Russell N. |
Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
|
JPH0764872A
(en)
|
1993-08-26 |
1995-03-10 |
Fujitsu Ten Ltd |
Data storage controller
|
US5578832A
(en)
|
1994-09-02 |
1996-11-26 |
Affymetrix, Inc. |
Method and apparatus for imaging a sample on a device
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5556752A
(en)
|
1994-10-24 |
1996-09-17 |
Affymetrix, Inc. |
Surface-bound, unimolecular, double-stranded DNA
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US5776905A
(en)
|
1996-08-08 |
1998-07-07 |
The Board Of Trustees Of The Leland Stamford Junior University |
Apoptotic regression of intimal vascular lesions
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
US6030961A
(en)
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
NZ503061A
(en)
|
1997-09-02 |
2001-08-31 |
Japan Energy Corp |
Cyclic tetrapeptide derivatives and use as anti-cancer agents
|
JPH11335375A
(en)
|
1998-05-20 |
1999-12-07 |
Mitsui Chem Inc |
Benzamide derivative having histone deacetylase inhibiting action
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US20070148228A1
(en)
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
US6723338B1
(en)
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
AU6932700A
(en)
|
1999-09-08 |
2001-04-10 |
Sloan-Kettering Institute For Cancer Research |
Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
|
CN1414971A
(en)
|
1999-12-08 |
2003-04-30 |
埃克斯西特治疗公司 |
Depsipeptide and congeners thereof for use as immunosuppressants
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
CA2317003A1
(en)
|
2000-02-28 |
2001-08-28 |
Hidenori Nakajima |
Gene expression potentiator
|
JP2001348340A
(en)
|
2000-06-07 |
2001-12-18 |
Yamanouchi Pharmaceut Co Ltd |
Histone deacetylase inhibitor
|
EP1302476B1
(en)
|
2000-07-17 |
2009-03-11 |
Astellas Pharma Inc. |
Reduced fk228 and use thereof
|
WO2002015921A2
(en)
*
|
2000-08-18 |
2002-02-28 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
EP1313872A1
(en)
*
|
2000-09-01 |
2003-05-28 |
Fujisawa Pharmaceutical Co., Ltd. |
A method of producing fr901228
|
WO2002055017A2
(en)
|
2000-11-21 |
2002-07-18 |
Wake Forest University |
Method of treating autoimmune diseases
|
CA2434269A1
(en)
|
2001-01-10 |
2002-07-18 |
The Government Of The United States Of America |
Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
|
JP4458746B2
(en)
*
|
2001-01-16 |
2010-04-28 |
グラクソ グループ リミテッド |
How to treat cancer
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
DE60227658D1
(en)
|
2001-05-02 |
2008-08-28 |
Univ California |
METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE, PSYCHIATRIC AND OTHER DISORDERS WITH DEACETYLASEINHIBITORS
|
ES2349349T3
(en)
|
2001-05-30 |
2010-12-30 |
The Regents Of The University Of Michigan |
SYNERGIC ASSOCIATION OF (-) - GOSIPOL WITH DOCETAXEL OR PACLITAXEL FOR CANCER TREATMENT.
|
US7171311B2
(en)
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
DK1426054T3
(en)
|
2001-08-21 |
2011-12-12 |
Astellas Pharma Inc |
Medical use of histone deacetylase inhibitor and method for evaluating its antitumor effect
|
WO2003017763A1
(en)
|
2001-08-24 |
2003-03-06 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
US20050123896A1
(en)
|
2001-10-25 |
2005-06-09 |
Benz Christopher C. |
Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
|
WO2003038060A2
(en)
|
2001-11-01 |
2003-05-08 |
The Regents Of The University Of Michigan |
Small molecule inhibitors targeted at bcl-2
|
WO2003053468A1
(en)
|
2001-12-21 |
2003-07-03 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
US20030134423A1
(en)
|
2002-01-04 |
2003-07-17 |
Chu Yong Liang |
Compounds for delivering substances into cells
|
US20030235588A1
(en)
|
2002-02-15 |
2003-12-25 |
Richon Victoria M. |
Method of treating TRX mediated diseases
|
US7488712B2
(en)
|
2002-02-20 |
2009-02-10 |
Kyushu Institute Of Technology |
Histone deacetylase inhibitors and methods for producing the same
|
NZ550185A
(en)
|
2002-03-04 |
2008-10-31 |
Merck Hdac Res Llc |
Methods of inducing terminal differentiation Methods of inducing terminal differentiation
|
WO2003083067A2
(en)
|
2002-03-28 |
2003-10-09 |
Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
|
MXPA04009761A
(en)
|
2002-04-05 |
2005-05-27 |
Fujisawa Pharmaceutical Co |
Depsipeptide for therapy of kidney cancer.
|
WO2003088954A1
(en)
|
2002-04-15 |
2003-10-30 |
Sloan-Kettering Institute For Cancer Research |
Combination therapy for the treatment of cancer
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
US20040002447A1
(en)
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
WO2004009771A2
(en)
|
2002-07-24 |
2004-01-29 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
ATE465757T1
(en)
|
2002-08-20 |
2010-05-15 |
Astellas Pharma Inc |
INHIBITOR OF THE DEGRADATION OF THE EXTRACELLULAR MATRIX OF ARTHRODIA CARTILAGE
|
EP1553948B1
(en)
|
2002-09-13 |
2011-08-24 |
Virginia Commonwealth University |
Combination of imatnib and a histone deacetylase inhibitor for the treatment of leukemia
|
SE0300098D0
(en)
|
2003-01-15 |
2003-01-15 |
Forskarpatent I Syd Ab |
Use of cyclin D1 inhibitors
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
EP1595952A4
(en)
|
2003-02-19 |
2008-05-21 |
Astellas Pharma Inc |
Method of estimating antitumor effect of histone deacetylase inhibitor
|
WO2004096289A1
(en)
|
2003-04-25 |
2004-11-11 |
Fujisawa Pharmaceutical Co |
Gene introduction efficiency enhancer
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
WO2005000332A2
(en)
|
2003-06-27 |
2005-01-06 |
Astellas Pharma Inc. |
Therapeutic agent for soft tissue sarcoma
|
PL1663978T3
(en)
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
JP4338734B2
(en)
|
2003-08-26 |
2009-10-07 |
メルク エイチディーエーシー リサーチ エルエルシー |
Cancer treatment with HDAC inhibitors
|
AU2004270150C1
(en)
|
2003-08-29 |
2011-07-14 |
Merck Hdac Research, Llc |
Combination methods of treating cancer
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
EP1670477A2
(en)
|
2003-09-18 |
2006-06-21 |
CombinatoRx, Incorporated |
Combinations of drugs for the treatment of neoplasms
|
CA2540108A1
(en)
|
2003-09-25 |
2005-04-07 |
Astellas Pharma Inc. |
Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
|
US8614318B2
(en)
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
CA2546178A1
(en)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
New use of adenovirus and nucleic acids coding therefor
|
US20060270016A1
(en)
|
2003-11-14 |
2006-11-30 |
Holm Per S |
Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
WO2005058298A2
(en)
|
2003-12-10 |
2005-06-30 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
US20050187148A1
(en)
|
2004-02-25 |
2005-08-25 |
Yoshinori Naoe |
Antitumor agent
|
US7951780B2
(en)
|
2004-02-25 |
2011-05-31 |
Astellas Pharma Inc. |
Antitumor agent
|
DE602005015559D1
(en)
|
2004-02-27 |
2009-09-03 |
Us Gov Health & Human Serv |
PHARMACODYNAMIC TESTS WITH FLOW CYTOMETRY
|
GB0405349D0
(en)
|
2004-03-10 |
2004-04-21 |
Univ Birmingham |
Cancer therapy and medicaments therefor
|
ITMI20040876A1
(en)
|
2004-04-30 |
2004-07-30 |
Univ Degli Studi Milano |
DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES
|
PT1591109E
(en)
|
2004-04-30 |
2008-09-05 |
Desitin Arzneimittel Gmbh |
Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
|
WO2005115149A2
(en)
|
2004-05-20 |
2005-12-08 |
Dow Agrosciences Llc |
Insectidal activity of a cyclic peptide
|
WO2005117930A2
(en)
|
2004-06-04 |
2005-12-15 |
Sloan-Kettering Institute For Cancer Research |
Use of thioredoxin measurements for diagnostics and treatments
|
WO2005123089A2
(en)
|
2004-06-10 |
2005-12-29 |
Kalypsys, Inc. |
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
|
US20060018921A1
(en)
|
2004-07-16 |
2006-01-26 |
Baylor College Of Medicine |
Histone deacetylase inhibitors and cognitive applications
|
WO2006027346A2
(en)
|
2004-09-06 |
2006-03-16 |
Altana Pharma Ag |
Novel pyrazolopyrimidines
|
JP2008520682A
(en)
|
2004-11-17 |
2008-06-19 |
ザ ユニヴァーシティー オヴ シカゴ |
Histone deacetylase inhibitors and methods of use thereof
|
US8889742B2
(en)
|
2004-11-30 |
2014-11-18 |
The Trustees Of The University Of Pennsylvania |
Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
|
WO2006060429A2
(en)
|
2004-12-03 |
2006-06-08 |
Novartis Ag |
Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
|
US20060128660A1
(en)
|
2004-12-10 |
2006-06-15 |
Wisconsin Alumni Research Foundation |
FK228 analogs and methods of making and using the same
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
EP1743654A1
(en)
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
|
US7943568B2
(en)
|
2005-09-30 |
2011-05-17 |
The Ohio State University Research Foundation |
Antitumor agents
|
WO2007049736A1
(en)
*
|
2005-10-28 |
2007-05-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Concentration crystallizer and method
|
US20090325156A1
(en)
|
2005-11-10 |
2009-12-31 |
Government of the United States of America, as Represented by Secretary, Dept. of Human Services |
Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
|
AU2006318652A1
(en)
|
2005-11-18 |
2007-05-31 |
Gloucester Pharmaceuticals, Inc. |
Metabolite derivatives of the HDAC inhibitor FK228
|
WO2008013589A2
(en)
|
2006-04-24 |
2008-01-31 |
Gloucester Pharmaceuticals |
Treatment of ras-expressing tumors
|
WO2007146730A2
(en)
|
2006-06-08 |
2007-12-21 |
Gloucester Pharmaceuticals |
Deacetylase inhibitor therapy
|
JP2009539862A
(en)
|
2006-06-09 |
2009-11-19 |
メリオン リサーチ Iii リミテッド |
Solid oral dosage form with toughener
|
US7857804B2
(en)
|
2006-09-01 |
2010-12-28 |
Mccaffrey Timothy A |
Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
|
BRPI0720991A8
(en)
|
2006-12-29 |
2016-03-15 |
Gloucester Pharmaceuticals Inc |
ROMIDEPSIN PREPARATION
|
EP2450049A1
(en)
|
2006-12-29 |
2012-05-09 |
Gloucester Pharmaceuticals, Inc. |
Romidepsin-based treatments for cancer
|
CN102276689A
(en)
|
2011-05-09 |
2011-12-14 |
中国药科大学 |
Chemical synthesis method of histone deacetylase inhibitor FK228 and application thereof
|